(PRESS RELEASE) BARCELONA — New scientific research, published in Animals, highlights the beneficial effect of Bioiberica’s Mobilee – which contains a high concentration of hyaluronic acid (HA) – in dogs with osteoarthritis. The research reveals that orally administered Mobilee – a route that has not been explored extensively until now – improves biomarkers of osteoarthritis in dogs, opening up possibilities for the development of novel animal health solutions to manage the condition.
The study, which explored the effects of orally administered HA (Mobilee) following tibial tuberosity advancement (TTA) surgery in dogs with cranial cruciate ligament rupture, is an exciting new development in animal health research. Adding to existing science in the field, it confirmed that Mobilee – a HA matrix containing a patented combination of HA, polysaccharides and collagen – supports joint health in dogs with knee osteoarthritis thanks to the synergistic effect of its three naturally-occurring components. This represents an exciting opportunity for animal health supplement manufacturers to enhance formulations with Mobilee and offer a new delivery format on the market – an oral-based HA solution that can be administered by dog owners.
The randomized, double-blind clinical study, conducted in 55 dogs, set out to evaluate the effect of orally administered HA (27 mg capsule once daily in dogs up to 26 kg and twice daily in dogs heavier than 26 kg) on synovial fluid concentrations of several selected biomarkers. At the beginning of the study, animals undergoing TTA surgery were divided into two groups: a control group which was given a placebo, and a group that received orally administered HA for 10 weeks. Synovial fluid samples were obtained before surgery and at 10 weeks postoperatively to measure concentrations of HA, haptoglobin, nitric oxide and paraoxonase-1 (PON-1). Researchers found that orally administered HA significantly improved biomarkers of osteoarthritis in dogs that received the supplement – after 10 weeks there was a significant increase in HA concentration in the synovial fluid and a decrease in PON-1 concentrations compared to baseline. HA concentration decreased in the placebo group over time. The positive changes in biomarkers of osteoarthritis as a result of postoperative oral administration of HA may represent a significant breakthrough in the management of joint health in dogs, and potentially other animals.
“Osteoarthritis is a common joint disorder in dogs – especially larger breeds and older dogs – that progressively produces biochemical, structural, mechanical and functional changes in the synovial joints,” says Sergi Segarra, R&D project manager, Human and Animal Health, Bioiberica. “HA is well-known to support joint health in animals with osteoarthritis. But it is usually injected to manage the condition, which requires a skilled professional to administer the dose. The Animals study is a significant milestone in this area of research because it indicates that orally administered HA may be beneficial too; highlighting the potential for joint conditions to be managed more easily in companion animals, particularly dogs.”
Mobilee is a hyaluronic acid matrix ingredient extracted from rooster comb with a high concentration of hyaluronic acid (60-75%) and other natural components, like polysaccharides (>10%) and collagen (>5%). To learn more about how Mobilee is supporting innovation in the animal health market, visit www.bioiberica.com.
